Document is current

Article History

Received: 23 January 2024

Accepted: 21 April 2024

First Online: 3 May 2024

Competing interests

: Hannah Wecker (HW), Stefanie Ziehfreund (SZ), and Ian Erhard (IE) have no conflicts of interest to declare. Daniel Maier (DM) received speaker honoraria from Free University Berlin and travel compensation from IQVIA. Fabienne A.U. Fox (FAUF) received travel compensation from IQVIA. Jörg Janne Vehreschild (JJV) has received personal fees from Merck / MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), University Hospital Freiburg/Congress and Communication, Academy for Infectious Medicine, University Manchester, German Society for Infectious Diseases (DGI), Ärztekammer Nordrhein, University Hospital Aachen, Back Bay Strategies, German Society for Internal Medicine (DGIM), Shionogi, Molecular Health, Netzwerk Universitätsmedizin, Janssen, NordForsk, Biontech, APOGEPHA and grants from Merck / MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), German Federal Ministry of Education and Research (BMBF), Deutsches Zetrum für Luft- und Raumfahrt (DLR), University of Bristol, Rigshospitalet Copenhagen, Network University Medicine. Alexander Zink (AZ) has been an advisor and/or received speaker's honoraria and/or received grants and/or participated in clinical trials of the following companies: AbbVie, Almirall, Amgen, Beiersdorf Dermo Medical, Bencard Allergie, BMS, Celgene, Eli Lilly, GSK, Janssen Cilag, Leo Pharma, Miltenyi Biotec, Novartis, Pfizer, Sanofi-Aventis, Takeda Pharma, UCB Pharma.